Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 Inhibitor After DC Cardioversion in Persistent AF and HFpEF
NCT07776054Phase 4Recruiting
- Sponsor
- Samsung Medical Center
- Start
- Feb 2024
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin, empagliflozin in Atrial fibrillation (AFib), sponsored by Samsung Medical Center. Started Feb 2024; status: recruiting.
02
Drugs
dapagliflozinempagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07776054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07776054.